

## ADHD Study with Superba™ Krill Oil shows significant positive effects

Krill Phospholipid EPA & DHA significantly improves brain function in boys with established diagnosis of ADHD

**12 October 2010 Oslo, Norway.** Aker BioMarine announces today that a clinical study in children with ADHD has demonstrated significant improvements in both clinical scores and in identified EEG patterns as compared to the typical “ADHD EEG pattern.” 18 boys (age 7 – 11 years) with attention deficit hyperactive disorder (ADHD) were supplemented daily with Superba™ Krill Oil for a period of 13 weeks. The EEG patterns for the study participants was compared to a database of more than 400 children with an established ADHD diagnosis, providing ample comparative data.

According to Hogne Vik MD, PhD, of Aker BioMarine, “This is an important observation identifying positive effects on the central nervous system (CNS) after supplementation of krill oil in humans. For the first time objective EEG-measurements - before and after a 90 day intervention period with krill oil – have confirmed observed improvements in a clinical CNS condition. The findings in this study will be published and followed-up with additional clinical studies in populations at risk for developing CNS disorders.”

The company will be providing detailed data in an Educational Presentation at the Supply Side West Trade Convention in Las Vegas on Friday, October 22, 2010 at 10AM.

“It is tempting to focus on the technology and data provided by this breakthrough study,” continued Vik. “But the participant’s parents reported significant improvements in attention and behavior, for example. In these kids real health benefits were realized, making this trial particularly satisfying for all involved.”

### About the technology

The technological platform applied is termed Database Supported Diagnostics (DSD). DSD requires a database of information about known cases. The information in the database is biological and health related data from groups of patients with known diseases as well as subjects that are deemed healthy with respect to the specific disease. Given such a database, contemporary multivariate statistical methods are applied in order to determine how well a given subject to be tested fits specific groups in the database. This is in many ways analogous to how an experienced medical doctor diagnoses a patient. The doctor looks for symptoms, (biological and health related data), and compares them to cases she or he has experienced or read about, (the database), which then leads to a diagnostic conclusion on his behalf, (statistical comparison to known cases).

Such a technological platform has been developed for dementia, with a particular focus on Alzheimer’s disease. Electroencephalography (EEG) is sensitive to the state of the metabolism of the brain. A database of information has been gathered from healthy control subjects as well as from dementia patients.

###

### About Superba™ Krill

Superba™ Krill is a pure, natural source of the health-promoting EPA & DHA omega-3 essential fatty acids and the naturally occurring antioxidant astaxanthin. The uniqueness of Superba Krill is that the omega-3 fatty acids are provided in phospholipid form. In vitro, in vivo and human clinical research has demonstrated the safety and efficacy of Superba Krill.



### **About Aker BioMarine**

Aker BioMarine is an integrated biotechnology company dedicated to the sustainable harvesting of krill and development of krill-derived biotech products. The company supplies biomarine ingredients through an optimized value chain from raw materials to customers. Aker BioMarine's Superba™ Krill products are provided with 100-percent traceability from the Antarctic sea to the end user. Aker BioMarine is the only krill harvester that has been awarded Marine Stewardship Council (MSC) Certification.



### **About Mentis Cura**

Mentis Cura is an innovative diagnostics company based in Iceland with a history from year 2000. The company specializes in early detection of CNS related diseases. Currently the focus is on dementia of the Alzheimer's type and differential diagnosis in the elderly. Mentis Cura has also developed technology able to track the progression of Alzheimer's and monitor treatment responders. The company has a separate program for detection of attention deficit hyperactive disorder (ADHD) in children, teenagers and adults. Icelandic and Norwegian investors support Mentis Cura. The described clinical study on Superba Krill Oil has utilized the Mentis Cura EEG assessment equipment. More information about Mentis Cura may be found at [www.mentiscura.com](http://www.mentiscura.com).

#### **For more information, please contact:**

Hogne Vik, EVP Documentation, Aker BioMarine, +47 24 13 00 00.

Audun Abelsnes, Chairman of the Board, Mentis Cura, +47 90 09 02 59

---